|
|
Article: Sirion Therapeutics Merges With Sytera to Develop New Treatments For Eye Disease.
- Article from:
- PR Newswire
- Article date:
- August 16, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla., Aug. 16 /PRNewswire/ -- Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceutical company, announced today that it has completed a merger with Sytera, Inc., a biopharmaceutical firm based in La Jolla, California committed to discovering new treatments for dry AMD (age- related macular degeneration). The announcement was made jointly by Sirion President and CEO Barry Butler, and Sytera Chairman and CEO Kenneth J. Widder, M.D. The financial terms were not disclosed. However, Sytera shareholders will be entitled to merger consideration in the form of stock and cash up front, as well as development and commercialization payments. Sytera is an Avalon ...
Related newspaper, magazine, and journal articles:
|
|
Article: Sirion Therapeutics Preclinical Studies: Two New ...
PR Newswire;
April 21, 2008 ;
700+ words
... ... April 21 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic ... Barry Butler, President and CEO of Sirion Therapeutics, Inc. "Sirion's targeted research ... Durezol(TM) is the trademark of Sirion Therapeutics, Inc. and is currently under review ...
|
|